Patient-based prediction algorithm of relapse after allo-HSCT for acute Leukemia and its usefulness in the decision-making process using a machine learning approach

Kyoko Fuse1 | Shun Uemura1 | Suguru Tamura1 | Tatsuya Suwabe1 | Takayuki Katagiri1 | Tomoyuki Tanaka1 | Takashi Ushiki1 | Yasuhiko Shibasaki2 | Naoko Sato3 | Toshio Yano3 | Takashi Kuroha3 | Shigeo Hashimoto3 | Tatsuo Furukawa3 | Miwako Narita4 | Hirohito Sone1 | Masayoshi Masuko2

Abstract

Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative therapy for high-risk acute leukemia (AL), some patients still relapse. Since patients simultaneously have many prognostic factors, difficulties are associated with the construction of a patient-based prediction algorithm of relapse. The alternating decision tree (ADTree) is a successful classification method that combines decision trees with the predictive accuracy of boosting. It is a component of machine learning (ML) and has the capacity to simultaneously analyze multiple factors. Using ADTree, we attempted to construct a prediction model of leukemia relapse within 1 year of transplantation. With the model of training data (n = 148), prediction accuracy, the AUC of ROC, and the κ-statistic value were 78.4%, 0.746, and 0.508, respectively. The false positive rate (FPR) of the relapse prediction was as low as 0.134. In an evaluation of the model with validation data (n = 69), prediction accuracy, AUC, and FPR of the relapse prediction were similar at 71.0%, 0.667, and 0.216, respectively. These results suggest that the model is generalized and highly accurate. Furthermore, the output of ADTree may visualize the branch point of treatment. For example, the selection of donor types resulted in different relapse predictions. Therefore, clinicians may change treatment options by referring to the model, thereby improving outcomes. The present results indicate that ML, such as ADTree, will contribute to the decision-making process in the diversified allo-HSCT field and be useful for preventing the relapse of leukemia.

KEYWORDS

acute leukemia, allogeneic hematopoietic stem cell transplantation, machine learning, patient-based prediction, relapse posttransplantation
1 | INTRODUCTION

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an established therapy that is associated with a high rate of curability for acute leukemia (AL). However, many patients still relapse after allo-HSCT, with common causes of death being relapse and leukemia-associated complications. Since salvage therapy is limited for these patients, their prognosis is very poor, with a probability of long-term survival of <20%. Thus, the establishment of prevention strategies against relapse after allo-HSCT is strongly needed.

Several pretransplant factors that may predict relapse after allo-HSCT were previously identified, such as patient backgrounds, including age, the Refined Disease Risk Index (rDRI), cytogenetic risk, and the Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI). Other technical components of allo-HSCT, including conditioning regimens, the selection of graft sources, and HLA discrepancies, are associated with relapse after allo-HSCT. These prognostic factors have been evaluated with conventional statistical techniques, such as univariate and multivariate analyses, which are model (hypothesis)-driven techniques; they start with a model and assess whether the data fit the suggested model. Although these techniques are popular and widely used in the analysis of medical records, they cannot simultaneously process multiple factors. Therefore, the complex network of multiple factors in a patient makes the patient-based prediction of relapse, which is generally useful in the bedside decision-making process regarding an indication for or the protocol of allo-HSCT, difficult.

The application of artificial intelligence (AI) to medicine, particularly machine learning (ML), a type of AI, has recently been attracting increasing attention. Multiple factors may be simultaneously analyzed, and AI may be applied to the examination of complex medical records. Since ML has the capacity to analyze multiple factors, we herein attempted to generate robust and accurate prediction models of relapse after allo-HSCT, which may be a useful tool in the bedside decision-making process to select a transplant method for reducing the relapse of leukemia.

2 | METHODS

2.1 | Patients

This analysis was a retrospective, data mining, and supervised learning study that included 217 AL patients. They underwent first allo-HSCT for AL at Niigata University Hospital (n = 148) and Nagaoka Red Cross Hospital (n = 69) between 1990 and 2016 and survived for more than 1 month after transplantation. The median follow-up of patients was 28.9 months (range 1.2-223.2 months). The diagnosis and classification of AL were based on criteria according to the WHO classification. Among 217 patients, 135 had acute myeloid leukemia (AML) and 82 had acute lymphoblastic leukemia (ALL). The median age of patients at allo-HSCT was 38 years (range 16-67 years old). To compare the risk of relapse, patients were stratified based on rDRI. (The definitions of rDRI and cytogenetic risk have been excerpted from reference No. 7 in Table S1.) According to rDRI, 14 (6.5%), 121 (55.8%), 51 (23.5%), and 31 (14.3%) patients were at low (LOW), intermediate (INT), high (HI), and very high risk (VH), respectively. Donors were related for 97 patients (44.7%) and were unrelated for 120 (55.3%). Graft sources were peripheral blood stem cells (PBSC) for 47 patients (21.7%, including PBSCs from 22 haploidentical donors), bone marrow (BM) for 123 (56.7%), and cord blood (CB) for 47 (21.7%). Myeloablative conditioning was used for 169 patients (77.9%) and with reduced intensity for 48 (22.1%). Among 22 patients with haploidentical donor graft, thymoglobulin in 14 and post cyclophosphamide in eight patients were used as conditioning. None of the patients received T-cell–depleted grafts in the present study. The HCT-CI score was low (0, 1, 2) for 183 (84.3%) patients and high (≥3) for 34 (15.7%) (Detailed information is shown in Table 1).

The present study was performed in accordance with the Japanese Ethical Guidelines for Medical and Health Research Involving Humans and approved by the Ethical Committee of our facilities.

2.2 | ML and ADTree

The alternating decision tree (ADTree), one component of the ML approach based on AI, is a successful classification method. ADTree combines decision trees with the predictive accuracy of boosting into a set of interpretable classification rules. Boosting influences the node-weighted score (NW) by repeating the sample classification with each node and calculating errors and classification confidence each time. Moreover, it repeats re-weighting the training samples to focus on the most problematic factor. (A more detailed principle is in reference No. 21).

Since ADTree learns previous data and predicts future classifications or discriminations, we used this algorithm in the present study as ML. ADTree was performed using WEKA software (Ver.3.9.1, Machine Learning Group at the University of Waikato, New Zealand, https://www.cs.waikato.ac.nz/ml/weka/index.html). The algorithm model was trained and tested using 10-fold cross-validation on the training data set (Niigata group) and validated again on the validation data set (Nagaoka group). The model evaluated the prediction accuracy and area under the curve (AUC) of the receiver operating characteristic (ROC) analysis, which discriminates the true prediction rate from a false prediction rate (FPR, also called the specificity). The tree was analyzed with the number of nodes between 6 and 11 and we adopted the number of nodes showing the highest $\kappa$-statistic value (Table S2).
2.3 Other statistical analyses

Group comparisons for continuous or categorical variables were evaluated using the Mann-Whitney U test or Fisher’s test. All times to events were computed from the date of transplantation. Overall survival (OS) was analyzed as the time until death or lost to the follow-up with the Kaplan-Meier estimator. The cumulative incidence of

No significant differences were observed between the training and validation sets.

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BM, bone marrow; CB, cord blood; HAPLO-PBSC, PBSC from haploidentical donors; HCT-CI, Hematopoietic Cell Transplantation-Comorbidity Index; HI, high risk; INT, intermediate risk; LOW, low risk; MAC, myeloablative conditioning; NRM, nonrelapse mortality; OS, overall survival; PBSC, peripheral blood stem cells; rDRI, the Refined Disease Risk Index; RFS, relapse-free survival; RIC, reduced intensity conditioning; TBI, total body irradiation; VH, very high risk.

**TABLE 1** Patient characteristics

| Factor | All | Niigata (training set) | Nagaoka (validation set) | P-value |
|--------|-----|------------------------|--------------------------|---------|
| Number of patients | N = 217 | N = 148 | N = 69 | |
| Age (range) | 38 y (10-67) | 38 y (10-66) | 39 y (14-67) | 0.196 |
| Age (%) | | | | |
| <40 y | 119 (54.8) | 83 (56.1) | 36 (52.2) | |
| ≤40 y | 98 (45.2) | 65 (43.9) | 33 (47.8) | 0.661 |
| Sex (%) | | | | |
| Male | 111 (51.2) | 74 (50.0) | 37 (53.6) | 0.663 |
| Female | 106 (48.8) | 74 (50.0) | 32 (46.4) | |
| Diagnosis (%) | | | | |
| AML | 135 (62.2) | 97 (65.5) | 38 (55.1) | 0.176 |
| ALL | 82 (37.8) | 51 (34.5) | 31 (44.9) | |
| with (9:22) | 31 (37.8) | 18 (8.7) | 13 (14.9) | 0.64 |
| Hospital (%) | | | | |
| Niigata | 148 (68.2) | | | |
| Nagaoka | 69 (31.8) | | | |
| rDRI (%) | | | | |
| LOW | 14 (6.5) | 10 (6.8) | 4 (5.8) | 0.574 |
| INT | 121 (55.8) | 78 (52.7) | 43 (62.3) | |
| HI | 51 (23.5) | 36 (24.3) | 15 (21.7) | |
| VH | 31 (14.3) | 24 (16.2) | 7 (10.1) | |
| Graft source (%) | | | | |
| BM | 123 (56.7) | 85 (57.4) | 38 (55.1) | 0.115 |
| PBSC | 25 (11.5) | 19 (12.8) | 6 (8.7) | |
| HAPLO-PBSC | 22 (10.1) | 18 (12.2) | 4 (5.8) | |
| CB | 47 (21.7) | 26 (17.6) | 21 (30.4) | |
| Donor type (%) | | | | |
| Unrelated | 120 (55.3) | 77 (52.0) | 43 (62.3) | 0.187 |
| Related | 97 (44.7) | 71 (48.0) | 26 (37.7) | |
| Conditioning (%) including MAC | | | | |
| RIC | 48 (22.1) | 38 (25.7) | 10 (14.5) | |
| Thymoglobulin | 14 (6.5) | 13 (8.8) | 1 (1.4) | |
| Post cyclophosphamide | 8 (3.7) | 5 (3.4) | 3 (4.3) | |
| HCT_CI score (%) | | | | |
| ≤2 | 183 (84.3) | 126 (85.1) | 57 (82.6) | 0.69 |
| ≤3 | 34 (15.7) | 22 (14.9) | 12 (17.4) | |
| NRM (%) | Yes | 42 (19.4) | 29 (19.6) | 13 (18.8) | 1 |
| No | 19 (8.8) | 17 (11.5) | 2 (2.9) | 0.041 |
| Using TBI (%) | Yes | 197 (91.2) | 131 (88.5) | 66 (97.1) | |
| No | 19 (8.8) | 17 (11.5) | 2 (2.9) | 0.041 |
| Relapse within 1 y (%) | Yes | 69 (31.8) | 51 (34.5) | 18 (26.1) | 0.273 |
| No | 197 (91.2) | 131 (88.5) | 66 (97.1) | |
| OS Months (range) | 28.9 (1.2-223.2) | 31.4 (1.2-223.2) | 27.3 (1.2-127.1) | 0.382 |
| RFS Months (range) | 20.6 (1.0-223.2) | 20.4 (1.0-223.2) | 20.7 (1.0-124.8) | 0.816 |
relapse (CIR) was assessed as the time of hematological relapse. In the case of no remission after allo-HSCT, the time of relapse was defined when blasts circulating in peripheral blood or BM were detected. The cut-off value for age used in adjustments in the multivariate analysis was set to 40 years.6 Univariate and multivariate analyses for CIR were performed using Fine and Gray models. Apart from ADTree, statistical analyses were performed using R-statistical software version 3.4.3 (The R Foundation for Statistical Computing) and EZR (Saitama Medical Center, Jichi Medical University), which is a graphical user interface for R.22 The significance of differences was considered to be $P < 0.05$ with a two-sided test.

3 | RESULTS

3.1 | Outcomes

One- and 3-year OS rates were 75.1% (95% CI: 68.8%-80.3%) and 59.1% (95% CI: 52.0%-65.6%), respectively (Figure 1A). One- and 3-year CIR rates were 33.8% (95% CI: 26.9%-40.0%) and 42.1% (95% CI: 34.7%-48.6%), respectively (Figure 1D). Most cases of relapse occurred within 1 year of allo-HSCT (Table 2, Figure 1D,1,1). There were six cases of no remission (2.8%) after allo-HSCT. Nonrelapse mortality (NRM) was 19.4% (n = 42) (Detailed information on NRM is shown in Table S3).

3.2 | Univariate and multivariate analyses for CIR

rDRI ($P < 0.0001$), the graft source ($P = 0.005$), and donor type (related or unrelated, $P = 0.014$) were identified as risk factors for relapse, while age ($P = 0.532$), sex ($P = 0.051$), the conditioning regimen ($P = 0.492$), TBI ($P = 0.051$), diagnosis ($P = 0.410$), and HCT-CI ($P = 0.526$) did not contribute to CIR in this cohort. rDRI ($P < 0.0001$) and the graft source ($P = 0.00687$) influenced OS, whereas the donor type did not ($P = 0.569$) (Table 2, Figure 1).

In the multivariate analysis, rDRI was identified as a risk factor for CIR ($P < 0.0001$), particularly rDRI; VH (HR 6.236, 95% CI: 1.696-22.93, $P = 0.006$) (Table 3).

3.3 | The model constructed with ADTree was generalized and highly accurate

Since most cases of relapse occurred within one year in this cohort, the presence or absence of relapse within one year of allo-HSCT was set as learning content in ADTree to construct a prediction model. We selected seven factors for learning:
## Table 2: Patient outcomes for OS and CIR

|                         | OS (%) (95% CI) |       |       |       | CIR (%) (95% CI) |       |       |       |
|-------------------------|----------------|-------|-------|-------|-----------------|-------|-------|-------|
|                         | 1 y            | 3 y   |       |       | 1 y            | 3 y   |       |       |
| **Patient outcomes**    |                |       |       |       | **P-value**     |       |       |       |
| **Age**                 |                |       |       |       | **P-value**     |       |       |       |
| <40 y                   | 75.6 (66.9-82.4)| 59.9 (50.3-68.3)| **P = 0.714**| 34.3 (24.9-42.5)| 39.9 (28.5-49.4)| **P = 0.532**|
| ≥40 y                   | 75.6 (69.2-82.0)| 58.2 (47.3-67.6)|               | 33.2 (22.7-42.3)| 39.9 (28.5-52.5)|               |
| **Sex**                 |                |       |       |       | **P-value**     |       |       |       |
| Male                    | 72.1 (62.7-79.5)| 54.7 (44.7-63.5)| **P = 0.123**| 36.9 (26.8-45.6)| 43.9 (33.1-52.9)| **P = 0.051**|
| Female                  | 78.3 (69.2-85.0)| 63.8 (53.3-72.5)|               | 30.7 (21.0-39.1)| 40.4 (29.8-49.3)|               |
| **Diagnosis**           |                |       |       |       | **P-value**     |       |       |       |
| AML                     | 73.3 (65.0-80.0)| 57.4 (48.3-65.5)| **P = 0.457**| 36.1 (27.2-44.0)| 43.1 (33.6-51.2)| **P = 0.410**|
| ALL                     | 78.0 (67.4-85.6)| 61.9 (67.4-85.6)|               | 29.9 (18.8-39.4)| 40.4 (27.9-50.7)|               |
| **Hospital**            |                |       |       |       | **P-value**     |       |       |       |
| Niigata (training data) | 77.7 (70.1-83.6)| 59.3 (50.6-66.9)| **P = 0.82** | 36.0 (22.7-27.6)| 46.9 (37.8-54.7)| **P = 0.097**|
| Nagaoka (validation data)| 69.6 (57.2-79.0)| 59.1 (46.0-70.0)|               | 28.5 (16.4-38.9)| 30.3 (17.8-40.9)|               |
| **rDRI**                |                |       |       |       | **P-value**     |       |       |       |
| LOW                     | 78.6 (47.2-92.5)| 78.6 (47.2-92.5)| **P < 0.0001**| 23.1 (0.0-42.9)| NA | **P < 0.0001** |
| INT                     | 88.4 (81.2-93.0)| 76.3 (67.2-83.1)|               | 15.8 (6.6-8.8)| 26.3 (1.5-17.5)|               |
| HI                      | 56.9 (42.2-69.1)| 40.0 (26.8-53.6)|               | 54.9 (9.0-37.6)| 62.8 (12.5-45.0)|               |
| VH                      | 51.6 (33.0-67.4)| 12.6 (3.3-28.3) |               | 76.5 (25.2-55.1)| 81.2 (32.4-58.9)|               |
| **Graft**               |                |       |       |       | **P-value**     |       |       |       |
| BMT                     | 78.9 (70.5-85.1)| 67.0 (57.8-74.6)| **P = 0.00687**| 29.9 (21.0-37.7)| 37.3 (27.7-45.6)| **P = 0.005**|
| PB                      | 64.0 (42.2-79.4)| 44.3 (23.4-63.4)|               | 51.6 (26.2-68.2)| 61.5 (34.5-77.3)|               |
| HAPLO-PB                | 63.6 (40.3-79.9)| 33.5 (14.6-53.7)|               | 56.1 (28.9-73.0)| 69.3 (38.0-84.8)|               |
| CBT                     | 76.6 (61.7-86.3)| 56.3 (38.9-70.5)|               | 23.6 (9.6-35.4)| 31.7 (15.7-44.7)|               |
| **Graft Related**       |                |       |       |       | **P-value**     |       |       |       |
| Related                 | 73.2 (63.2-80.9)| 56.4 (45.6-65.8)| **P = 0.569** | 40.9 (30.0-50.2)| 51.9 (40.2-61.2)| **P = 0.014**|
| Unrelated               | 76.7 (68.8-83.3)| 61.4 (51.6-69.7)|               | 27.8 (18.9-35.7)| 33.8 (24.3-42.2)|               |
| **Conditioning**        |                |       |       |       | **P-value**     |       |       |       |
| MAC                     | 74.6 (67.3-80.5)| 60.8 (52.8-67.9)| **P = 0.598** | 32.8 (25.1-39.8)| 40.6 (32.3-47.9)| **P = 0.492**|
| RIC                     | 77.1 (62.5-85.6)| 52.9 (36.8-66.6)|               | 37.1 (21.3-49.7)| 47.1 (29.9-60.1)|               |
| **Using TBI**           |                |       |       |       | **P-value**     |       |       |       |
| No                      | 68.4 (42.8-84.4)| 45.6 (22.3-66.3)| **P = 0.303** | 47.4 (19.4-65.6)| 32.6 (28.0-80.5)| **P = 0.051**|
| Yes                     | 75.6 (69.0-81.0)| 60.5 (53.0-72.5)|               | 32.6 (25.5-39.1)| 40.5 (32.8-47.3)|               |
| **HCT_CI score**        |                |       |       |       | **P-value**     |       |       |       |
| ≤2                      | 76.0 (69.1-81.5)| 59.2 (51.4-66.2)| **P = 0.777** | 35.0 (27.5-41.7)| 42.8 (34.8-49.8)| **P = 0.526**|
| ≤3                      | 70.6 (52.2-83.0)| 58.4 (40.1-72.9)|               | 27.3 (9.2-41.8)| 38.6 (17.6-54.2)|               |

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BM, bone marrow; CB, cord blood; CIR, cumulative incidence of relapse; HAPLO-PBS, PBSC from haploidentical donors; HCT-CI, Hematopoietic Cell Transplantation-Comorbidity Index; HI, high risk; INT, intermediate risk; LOW, low risk; MAC, myeloablative conditioning; OS, overall survival; PBSC, peripheral blood stem cells; rDRI, the Refined Disease Risk Index; RIC, reduced intensity conditioning; TBI, total body irradiation; VH, very high risk.
and NW > 0 a higher relapse risk. For example, among the same node level, donor type (node 4), an unrelated donor showed a lower risk (NW, −0.249) than a related donor (NW, 0.313), and this result was the same as that in the univariate analysis on CIR. The final judgment of the AL relapse prediction was performed by summing all the nodes through which it passed (NW sum). The NW sum > 0 predicted relapse and < 0 predicted no relapse in this model. According to the model, if ALL patients with rDRI HI receive allo-HSCT using the RIC regimen and a related donor, the NW sum is −0.742 < 0, which predicts no relapse. Moreover, if the diagnosis is AML, the NW sum is 0.147 > 0, which predicts relapse within 1 year of allo-HSCT. However, in the case of an unrelated donor, the relapse prediction changes; the NW sum becomes −1.475 (age ≤ 40 years) and −0.469 > 0 (>40 years), indicating no relapse (Figure 3).

### 4 | DISCUSSION

Historically, AI and ML were initially developed for image and voice recognition and were subsequently applied to the analysis of data sets of large volumes, such as purchase records. AI and ML are now expected to handle and analyze complex medical records. When clinical study reports were searched using the following keywords on Pubmed: “machine learning”, “diagnosis”, and “prognosis”, 18 reports in 2000 and 185 in 2010 were hit. Between 2015 and 2018, approximately 1000 reports were searched for each year.

Some groups in the hematology field also attempted to use AI and ML. Shouval et al analyzed the data of approximately 20 000 patients in the European Society for Blood and Marrow Transplantation with ADTree and succeeded in constructing a prediction model of early NRM after allo-HSCT. They also evaluated the same data set and compared it with six other ML programs. All programs showed high predictability and versatility. AI and ML have also been applied in the following fields: the morphological analysis of blood cells, the identification of prognostic factors of ALL in childhood, and the differential diagnosis of hematological diseases.

High CIR rates after allo-HSCT represent a clinical issue that needs to be resolved in adverse risk AL. To improve outcomes, attempts are being made to develop strategies that reduce the risk of relapse. Many technical options are now available for allo-HSCT. Furthermore, with the establishment of a safer method for elderly patients, the number of patients indicated for allo-HSCT has increased. Since the technique of allo-HSCT is very diversified and complex, some clinicians may have difficulties selecting treatment options that improve the outcomes of each patient.
The concept of this analysis is “Changing therapy options to avoid leukemia relapse according to model predictions”. We focused on what may be modified factors (such as conditioning or the graft source) and what are fixed factors (including age, disease status, or diagnosis) in the analysis prior to transplantation. Furthermore, a unique point in our analysis was the visualization of the branch point of treatment using ADTree (Figure 2). Although previous studies using AI or ML mainly aimed at discrimination and diagnosis, as described above, we herein attempted to construct patient-based treatment algorithms by applying AI.

In high-risk AML, the branch point of therapeutic options from our simulation was the donor type (Figure 3). By referring to the prediction results of ADTree, clinicians may change treatment options, thereby improving outcomes. In the present results (Figure 2, at node 1), INT showed NW -0.565, whereas LOW together with HI and VH showed NW 0.447, indicating that LOW was a higher relapse risk than INT, which was unexpected. LOW patients generally do not need to receive allo-HSCT at first remission. LOW patients who received allo-HSCT failed first-line therapy, and may have a worse status than other patients; therefore, we speculated that ADTree judged LOW as a higher relapse risk than INT. This result suggests that ADTree provides us with different information and interactions from existing knowledge.

Medical records contain very diverse information. Patients have different backgrounds that are generally not ideal for statistical analyses. Classical statistical techniques require “noise” to be removed from data when medical records are analyzed. Model (hypothesis)-driven statistical techniques have identified many prognostic factors, but have been unable to adjust for each patient with individual factors, which are sometimes considered to be “noise”.18 These disadvantages have led to difficulties in the construction of “individualized transplantation therapy” for patients in clinical settings. One of the differences between the conventional method and ML is that the former focuses on proving “whether the hypothesis...
TABLE 4  The actual number of patients and the prediction number of relapse

| Training set (n = 148) | Prediction | No relapse | Relapse | Total |
|------------------------|------------|------------|---------|-------|
| Actual number          |            |            |         |       |
| No relapse             | 84         | 13         | 97      |       |
| Relapse                | 19         | 32         | 51      |       |
| Total                  | 103        | 45         | 148     |       |

| Validation set (n = 69) | Prediction | No relapse | Relapse | Total |
|-------------------------|------------|------------|---------|-------|
| Actual number           |            |            |         |       |
| No relapse              | 40         | 11         | 51      |       |
| Relapse                 | 9          | 9          | 18      |       |
| Total                   | 49         | 20         | 69      |       |

TABLE 5  Comparison of predictability

| Niigata group (Training set) | Accuracy | AUC | ρ-statistic | TPR   | TNR   | FPR   | FNR   |
|------------------------------|----------|-----|-------------|-------|-------|-------|-------|
| 78.4%                        | 0.746    | 0.508 |            | 0.627 | 0.866 | 0.134 | 0.373 |

| Nagaoka group (Validation set) | Accuracy | AUC | ρ-statistic | TPR   | TNR   | FPR   | FNR   |
|-------------------------------|----------|-----|-------------|-------|-------|-------|-------|
| 71.0%                         | 0.667    | 0.274 |            | 0.500 | 0.784 | 0.216 | 0.500 |

In this prediction model, true-positive rate (TPR, also called the sensitivity) and false-positive rate (FNR, it shows miss rate) in relapse were not sufficiently. However, true-negative rate (TNR, also called specificity) was high- and false-positive rate (FPR, it means probability of false alarm) in relapse was very low. Therefore, clinicians may consider changes in treatment options if relapse is predicted.

AUC: area under the curve, Accuracy = (true positive + true negative)/ all, TPR = true positive/ (true positive + false negative) = 1-FNR, FNR = false negative/ (false negative + true positive) = 1-TPR, TNR = true negative/ (true negative + false positive) = 1-FPR, FPR = false positive/ (false positive + true negative) = 1-TNR.

FIGURE 3  Example of a simulation. In high-risk AML, the branch point of therapeutic options was the donor type from our simulation.
is true”, whereas ML, such as ADTree, “attempts to explain previous data and predict the future”. This difference is expected to be an advantage when using ML for the analysis of medical records.

The limitation of the present study is that the volume of patient data for ADTree to learn was relatively small. The higher the amount of learning, the greater the prediction accuracy, and, thus, it is possible to construct a model that is more useful for the bedside decision-making process by clinicians. Furthermore, other factors, such as information on chromosome or genetic abnormalities and the chemotherapy protocol, HLA discrepancy rate, and the posttransplant maintenance therapy (donor lymphocyte infusion, azacytidine, et al) are needed to develop ADTree. The planned DLI and targeted posttransplant therapy may be effective at preventing relapse, but this study did not include the patients who received these therapies, so we could not evaluate their effects. The addition of social environments and educational history, which are complex factors, may also be beneficial.29 The outcomes of allo-HSCT may vary among transplant centers. The present results suggest that ADTree is currently applicable to bedside decision-making in single institutions.

In conclusion, we attempted to generate robust and accurate prediction models of relapse after allo-HSCT that will contribute to preventing the relapse of leukemia. AI and ML, such as ADTree, may improve the decision-making process for therapy in the diversified allo-HSCT field. The usefulness of AI and ML is now being demonstrated, and further clinical applications are expected in the future.

CONFLICT OF INTEREST

Nothing to report.

AUTHOR CONTRIBUTIONS

KF designed this study, analyzed the data, and wrote the manuscript. TT, YS, TF, MN, and HS participated in the conception of the study and in providing patient data. MM revised the manuscript and provided administrative support for the study. All authors reviewed and approved the final version of the manuscript.

ORCID

Kyoko Fuse https://orcid.org/0000-0002-8273-9436

REFERENCES

1. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukemia. Lancet. 2013;381(9881):1943-1955.
2. Short NJ, Rytting ME, Cortes JE. Acute myeloid leukemia. Lancet. 2018;392(10147):593-606.
3. D’Souza A, Lee S, Zhu X, Pasquini M. Current use and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2017;23(9):1417-1421.
4. Giebel S, Marks DJ, Boissel N, et al. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2018;54(6):798-809.
5. Tsirigotis P, Byrne M, Schmid C, et al. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transplant. 2016;51(11):1431-1438.
6. Sorror ML, Storb RF, Sandmaier BM, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014;32(29):3249-3256.
7. Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123(23):3664-3671.
8. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349-2361.
9. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-2919.
10. Scott BL, Pasquini MC, Logan BR, et al. Myelosuppressive or reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35(11):1154-1161.
11. Rambaldi A, Grassi A, Masciulli A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015;16(15):1525-1536.
12. Fleischhauer K, Hsu KC, Shaw BE. Prevention of relapse after allogeneic hematopoietic cell transplantation by donor and cell source selection. Bone Marrow Transplant. 2018;53(12):1498-1507.
13. Lee SJ, Logan B, Westervelt P, et al. Comparison of patient-reported outcomes in 5-Year survivors who received bone marrow vs peripheral blood unrelated donor transplantation: long-term follow-up of a randomized clinical trial. JAMA Oncol. 2016;2(12):1583-1589.
14. Milano F, Gooley T, Wood B, et al. Cord-blood transplantation in patients with minimal residual disease. N Engl J Med. 2016;375(10):944-953.
15. Atsuta Y, Kanda J, Takanashi M, et al. Different effects of HLA disparity on transplant outcomes after single-unit cord blood transplantation between pediatric and adult patients with leukemia. Haematologica. 2013;98(5):814-822.
16. Wang Y, Wu D-P, Liu Q-F, et al. Donor and recipient age, gender and ABO incompatibility regardless of donor source: validated criteria for donor selection for haematopoietic transplants. Leukemia. 2018;32(2):492-498.
17. Solh M, Zhang XU, Connor K, et al. Donor type and disease risk predict the success of allogeneic hematopoietic cell transplantation: A single-center analysis of 613 adult hematopoietic cell transplantation recipients using a modified composite endpoint. Biol Blood Marrow Transplant. 2017;23(12):2192-2198.
18. Shouval R, Bondi O, Mishan H, Shimoni A, Unger R, Nagler A. Application of machine learning algorithms for clinical predictive modeling: a data-mining approach in SCT. Bone Marrow Transplant. 2014;49(3):332-337.
19. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.
20. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.
21. Freund Y, Mason L. The alternating decision tree learning algorithm. In: ICML ’99 Proceedings of the Sixteenth International Conference on Machine Learning. San Francisco, CA: USA Morgan Kaufmann Publishers Inc; 1999:124-133.
22. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452-458.
23. Shouval R, Labopin M, Bondi O, et al. Prediction of allogeneic hematopoietic stem-cell transplantation mortality 100 days after transplantation using a machine learning algorithm: A European group for blood and marrow transplantation acute leukemia working party retrospective data mining study. J Clin Oncol. 2015;33(28):3144-3151.
24. Shouval R, Labopin M, Unger R, et al. Prediction of hematopoietic stem cell transplantation related mortality- Lessons learned from the In-Silico approach: A European society for blood and marrow transplantation acute leukemia working party data mining study. PLoS ONE. 2016;11(3):e0150637.
25. Rodellar J, Alférez S, Acevedo A, Molina A, Merino A. Image processing and machine learning in the morphological analysis of blood cells. Int J Lab Hematol. 2018;40(Suppl 1):46-53.
26. Pan L, Liu G, Lin F, et al. Machine learning applications for prediction of relapse in childhood acute lymphoblastic leukemia. Sci Rep. 2017;7(1):7402.
27. Bigorra L, Larriba I, Gutiérrez-Gallego R. Machine learning algorithms for accurate differential diagnosis of lymphocytosis based on cell population data. Br J Haematol. 2018.
28. Devine SM, Owzar K, Blum W, et al. Phase II study of allogeneic transplantation for older patients with acute Myeloid Leukemia in first complete remission using a reduced-intensity conditioning regimen: Results from cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and marrow transplant clinical trial network 0502. J Clin Oncol. 2015;33(35):4167-4175.
29. Østgård L, Notgaard M, Medeiros BC, et al. Effects of education and income on treatment and outcome in patients with acute myeloid Leukemia in a tax-supported health care system: A national population-based cohort study. J Clin Oncol. 2017;35(32):3678-3687.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Fuse K, Uemura S, Tamura S, et al. Patient-based prediction algorithm of relapse after allo-HSCT for acute Leukemia and its usefulness in the decision-making process using a machine learning approach. Cancer Med. 2019;8:5058–5067. https://doi.org/10.1002/cam4.2401